The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVTC.Y | -40.78% | -79.51% | -27.15% | +179% |
| S&P | +13.19% | +87.83% | +13.42% | +378% |
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $191.51M | -5.7% |
| Gross Profit | -$0.07M | -100.4% |
| Gross Margin | -0.04% | -9.9% |
| Market Cap | $1.29B | -0.4% |
| Market Cap / Employee | $0.27M | 4.2% |
| Employees | 4.8K | -4.4% |
| Net Income | -$50.35M | -15.6% |
| EBITDA | -$30.11M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $204.49M | -20.8% |
| Accounts Receivable | $182.92M | 19.8% |
| Inventory | 36.6 | -8.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $455.60M | -2.0% |
| Short Term Debt | $113.83M | 90.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.20% | -0.1% |
| Return On Invested Capital | -3.60% | -3.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$99.60M | -725.9% |
| Operating Free Cash Flow | -$75.34M | -266.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.36 | 1.10 | 1.51 | 1.30 | 8.45% |
| Price to Sales | 1.71 | 1.40 | 1.77 | 1.55 | 0.83% |
| Price to Tangible Book Value | 1.97 | 1.58 | 2.29 | 2.03 | 17.65% |
| Price to Free Cash Flow TTM | 45.10 | - | |||
| Enterprise Value to EBITDA | -203.33 | -89.47 | -52.49 | - | |
| Free Cash Flow Yield | 2.2% | - | |||
| Return on Equity | -19.0% | -20.4% | -16.3% | -17.5% | 7.72% |
| Total Debt | $455.02M | $517.10M | $542.41M | $569.42M | 8.54% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
